Pathologic gambling: Biological and clinical considerations

Journal of Addiction Medicine

Volumn 3, Issue 3, 2009, Pages 111-119

  Topf, Jocelyn L ^a   Yip, Sarah W ^a   Potenza, Marc N ^b  

^a Yale University School of Medicine   (United States)

^b SAC 208   (United States)

Author keywords

Impulse control disorders; Pathologic gambling; Sub stance use disorders

Indexed keywords

EID: 70349243178     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31819b7bff     Document Type: Article

References (93)

1. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Hoffmann J, Gerstein D, Larison C, et al. Report to the National Gambling Impact Study Commission. 1999. Available at: http:// wwwngiscgov/reports. Accessed April 14, 1999.
3. James KC. National Gambling Impact Study Commission: Final Report to Congress. 1999. Available at: http://wwwngiscgov/reports/ fullrpthtml. Accessed August 18, 1999.
4. Petry NM, Stinson FS, Grant BF. Co-morbidity of DSM-IV pathological gambling and other psychiatric disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66:564-574.
5. Desai RA, Desai MM, Potenza MN. Gambling, health and age: Data from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Addict Behav. 2007;21:431-440.
6. National Research Council. Pathological Gambling: A Critical Review. Washington, DC: National Academy Press; 1999.
7. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual ofMental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
8. DeCaria CM, Begaz T, Hollander E. Serotonergic and noradrenergic function in pathological gambling. CNS Spectr. 1998;3:38-45.
9. Pallanti S, Bernardi S, Quercioli L, et al. Serotonin dysfunction in pathological gamblers: Increased prolactin response to oral m-CPP versus placebo. CNS Spectr. 2006;11:956-964.
10. Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ. Serotonin and gambling dependence. Hum Psychopharmacol. 1991;6:9-12.
11. Ratsma JE, van Der Stelt O, Gunning WB. Neurochemical markers of alcoholism vulnerability in humans. Alcohol Alcohol. 2002;37:522-533.
12. Potenza MN, Hollander E. Pathological Gambling and Impulse Control Disorders. In: Davis KL, Charney D, Coyle JT, et al, eds. Neuropsy- chopharmacology: The 5th Generation of Progress. Baltimore: Lippin- cott Williams and Wilkins, 2002:1725-1742.
13. Nordin C, Eklundh T. Altered CSF 5-HIAA disposition in pathological male gamblers. CNS Spectr. 1999;4:25-33.
14. Nordin C, Sjodin I. CSF monoamine patterns in pathological gamblers and healthy controls. JPsychiatr Res. 2006;40:454-459.
15. Fils-Aime ML, Eckardt MJ, George DT, et al. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry. 1996;53:211-216.
16. Cardinal RN. Neural systems implicated in delayed and probabilistic reinforcement. Neural Netw. 2006;19:1277-1301.
17. Perez de Castro I, Ibanez A, Saiz-Ruiz J, et al. Genetic contribution to pathological gambling: Possible association between a functional DNA polymorphism at the serotonin transporter gene (5-HTT) and affected men. Pharmacogen. 1999;9:397-400.
18. Ibanez A, Blanco C, Perez de Castro IP, et al. Genetics of pathological gambling. J Gambl Stud. 2003;19:11-22.
19. Shinohara K, Yanagisawa A, Kagota Y, et al. Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system sub stances and heart rate. Appl Human Sci. 1999;18:37-42.
20. Meyer G, Schwertfeger J, Exton MS, et al. Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinol. 2004; 29:1272-1280.
21. Bergh C, Eklund T, Sodersten P, et al. Altered dopamine function in pathological gambling. Psychol Med. 1997;27:473-475.
22. Zack M, Poulos C. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsyh- copharmacol.2004;29:195-207. (Pubitemid 38068030)
23. Zack M, Poulos C. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychop- harmacol. 2007;32:1678-1686.
24. Fong T, Kalechstein A, Bernhard B, et al. A double-blind, placebo- controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89:298-303.
25. McElroy S, Nelson E, Welge J, et al. Olanzapine in the treatment of pathological gambling: A negative randomized placebo-controlled trial. JClin Psychiatry. 2008;69:433-440.
26. Potenza MN, Voon V, Weintraub D. Drug insight: Impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Practice Neurosci. 2007;3:664-672.
27. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969-973.
28. Weintraub D, Koester J, Potenza MN, et al. Dopaminergic therapy and impulse control disorders in Parkinson's disease: A cross-sectional study of over 3, 000 patients. Movement Disorder Society Annual Convention, Chicago, IL, June 2008.
29. Comings DE. The molecular genetics of pathological gambling. CNS Spectr. 1998;3:20-37.
30. Kreek MJ, Nielsen DA, Butelman ER, et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci. 2005;8:1450-1457.
31. Dick DM, Wang JC, Plunkett J, et al. Family-based association analyses of alcohol dependence phenotypes across DRD2 and neighboring gene ANKK1. Alcohol Clin Exp Res. 2007;31:1645-1653.
32. Sabbatini da Silva Lobo D, Vallada HP, Knight J, et al. Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud. 2007; 23:421-433.
33. Weinshenker D, Schroeder JP. There and back again:A tale of norepi-nephrine and drug addiction. Neuropsychopharmacol.2007;32:1433-1451.
34. Roy A, Adinoff B, Roehrich L, et al. Pathological gambling. A psycho- biological study. Arch Gen Psychiatry. 1988;45:369-373.
35. Roy A, De Jong J, Linnoila M. Extraversion in pathological gamblers. Correlates with indexes of noradrenergic function. Arch Gen Psychiatry. 1989;46:679-681.
36. Potenza MN, Fiellin DA, Heninger GR, et al. Gambling: An addictive behavior with health and primary care implications. J Gen Int Med. 2002;17:721-732.
37. Kalivas PW, Volkow ND. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry. 2005;162:1403-1413.
38. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gamblers: An fMRI study. Arch Gen Psychiatry. 2003;60: 828-836.
39. Breiter H, Rauch SL. Functional MRI and the study of OCD: From symptom provocation to cognitive-behavioral probes of cortico-striatal systems and the amygdala. Neuroimage. 1996;4:s127-s138.
40. Bechara A. Risky business: Emotion, decision-making, and addiction. J Gambling Stud. 2003;19:23-51.
41. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: Relationships to drug addictions. Biochem Pharmacol 2008;75:63-75.
42. Potenza MN, Leung H-C, Blumberg HP, et al. An fMRI stroop study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160:1990-1994.
43. Blumberg HP, Leung HC, Skudlarski P, et al. A functional magnetic resonance imaging study of bipolar disorder: State- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry. 2003; 60:601-609.
44. Tanabe J, Thompson L, Claus E, et al. Prefrontal cortex activity is reduced in gambling and nongambling substance users during decision- making. Hum Brain Mapp. 2007;28:1276-1286.
45. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci. 2005;8:147-148.
46. Knutson B, Fong GW, Bennett SM, et al. A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: Characterization with rapid event-related fMRI. Neuroimage. 2003;18:263-272.
47. McClure S, Laibson DI, Loewenstein G, et al. Separate neural systems value immediate and delayed monetary rewards. Science. 2004;306: 503-507.
48. Hollander E, Pallanti S, Rossi NB, et al. Imaging monetary reward in pathological gamblers. World JBiol Psychiatry. 2005;6:113-120.
49. Wrase J, Schlagenhauf F, Kienast T, et al. Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics. Neuroimage. 2007;35:787-794.
50. Pearlson GD, Shashwath M, Andre T, et al. Abnormal fMRI activation of reward circuitry in current versus former cocaine abusers. American College of Neuropsychopharmacolgy. Boca Raton, FL, December 2007.
51. Bjork J, Knutson B, Fong GW, et al. Incentive-elicited brain activation in adolescents: Similarities and differences from young adults. J Neurosci. 2004;24:1793-1802.
52. Hommer DW, Bjork JM, Knutson B, et al. Motivation in children of alcoholics. Alcohol Clin Exp Res. 2004;28:22A.
53. Potenza MN. The neurobiology of pathological gambling and drug addiction: An overview and new findings. Phil Trans Royal Soc B. 2008;363:3181-3189.
54. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47:813-817.
55. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: A multi-center randomized controlled trial. Int Clin Psychopharmacol. 2003;18:243-249.
56. Kim S, Grant JE, Adson DE, et al. A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling disorder. J Clin Psychiatry. 2002;63:501-507.
57. Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling: A pilot study. J Clin Psychiatry. 2005;66:28-33.
58. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: An Open-Label Pilot Study with Double- Blind Discontinuation. Int Clin Psychopharmacol. 2006;21:203-209.
59. Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism;Implications for treatment. CNS Drugs. 2004;18:1105-: 1118.
60. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;9:159-164.
61. O'Brien CP. Anticraving medications for relapse prevention: A possible new class of psychoactive medications. Am J Psychiatry. 2005;162: 1423-1431.
62. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914-921.
63. Grant JE, Kim SW, Hartman B. A double-blind, placebo-controlled study of the opioid antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69:783-789.
64. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303-312.
65. Grant JE, Kim SW, Hollander E, et al. Predicting treatment response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacol. 2008;200:521-527.
66. Slutske WS, Eisen S, True WR, et al. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry. 2000;57:666-674.
67. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacol. 2003;28:1546-1552.
68. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: A randomized single-blind study. JClin Psychiatry. 2002;63:559-564.
69. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137-145.
70. Black DW. An open-label trial of bupropion in the treatment of pathological gambling. JClin Psychopharmacol. 2004;24:108-110.
71. Black DW, Arndt S, Coryell W, et al. Bupropion in the treatment of pathological gambling: A randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol. 2007;27:143-150.
72. Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry. 2005;66:1492-1493.
73. Coric V, Kelmendi B, Pittenger C, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillo- mania. J clin psychiatry. 2007;68:170-171.
74. Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol. 2007;27:227-229.
75. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: A pilot study. Biol Psychiatry. 2007;62:652-657.
76. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psych. 2008;165:179-187.
77. McConaghy N, Armstrong MS, Blaszczynski A, et al. Controlled comparison of aversive therapy and imaginal desensitization in compulsive gambling. Br JPsychiatry. 1983;142:366-372.
78. McConaghy N, Blaszczynski A, Frankova A. Comparison of imaginal desensitisation with other behavioural treatments of pathological gambling. A two- to nine-year follow-up. Br J Psychiatry. 1991;159:390-393.
79. Echeburua E, Baez C, Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in psychological treatment of pathologling. Behav Cog Psychother. 1996;24:51-72.
80. Echeburua E, Fernandez-Montalvo J, Baez C. Relapse prevention in the treatment of slot-machine gambling: Long-term outcome. Behav Ther. 2000;31:351-364.
81. Sylvain C, Ladouceur R, Boisvert J-M. Cognitive and behavioral treatent of pathological gambling: A controlled study. J Consult Clin Psychol. 1997;65:727-732.
82. Ladouceur R, Sylvain C, Boutin C, et al. Cognitive treatment of pathological gambling. JNerv Ment Dis. 2001;189:774-780.
83. Ladouceur R, Sylvain C, Boutin C, et al. Group therapy for pathological gamblers: A cognitive approach. Behav Res Ther. 2003;41:587-596.
84. Hodgins D, Currie SR, el-Guebaly N. Motivational enhancement and self-help treatments for problem gambling. JConsult Clin Psychology. 2001;69:50-57.
85. Petry NM. Gamblers Anonymous and cognitive-behavioral therapies for pathological gamblers. J Gambling Stud. 2005;21:27-33.
86. Stewart RM, Brown RI. An outcome study of Gamblers Anonymous. Br J Psychiatry. 1988;152:284-288.
87. Petry NM. Patterns and correlates of gamblers anonymous attendance in pathological gamblers seeking professional treatment. Addict Behav. 2003;28:1049-1062.
88. Petry NM, Alessi SM, Carroll KM, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychology. 2006;74:555-567.
89. Grant JE, Levine L, Kim D, et al. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162:2184-2188.
90. Morasco BJ, vom Eigen KA, Petry NM. Severity of gambling is associated with physical and emotional health in urban primary care patient. Gen Hosp Psychiatry. 2006;28:94-100.
91. Ladd GT, Petry NM. Disordered gambling among university-based medical and dental patients: A focus on internet gambling. Psychol Addict Behav. 2002;16:76-79.
92. Pasternak AV, Fleming MF. Prevalence of gambling disorders in a primary care setting. Arch Fam Med. 1999;8:515-520.
93. Desai RA, Potenza MN. Problem and pathological gambling in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. ePub June 16, 2009:e1-e8.